Pascal Touchon 🇫🇷 | Cell Therapy, Jeito, Kymriah | E49  episode artwork

EPISODE · Jan 6, 2026 · 1H 14M

Pascal Touchon 🇫🇷 | Cell Therapy, Jeito, Kymriah | E49

from Flot.bio x Philip Hemme · host Flot.bio

Pascal Touchon unpacks why the next CAR-T innovations, including allogeneic and in vivo therapies, are going to be so exciting.The cell therapy master outlines his central role in bringing two first‑in‑class cell therapies to patients: Kymriah, the first approved CAR‑T, and Ebvallo, the first approved allogeneic T‑cell therapy. We also explore his new position as an operating partner at Jeito and how we need to work harder to find Europe’s hidden biotech gems.-----------------------------------------------------------------------Get expert legal advisory support for growing your biotech from Osborne Clarke at https://bit.ly/oc-flotbio----------------------------------------------------------------------⭐️ ABOUT THE SPEAKERWith many years of experience in big pharma, Pascal had top-level positions at Novartis Oncology. He later served as CEO, and most recently Chairman, of Atara Biotherapeutics. Alongside his Jeito role, he sits on the boards of companies including Ipsen, Medincell, Catalym, Xylocor and CDR-Life.🔗 LINKS MENTIONEDJeito’s website: https://www.jeito.life/en/home/Stefano Portolano, Azafaros | Rare Diseases, Small Molecules Revival | E40: https://www.youtube.com/watch?v=gdaPW7xg_qkOtello Stampacchia, Omega Funds 🇮🇹 | Competition, Boston & Pasta | E18: https://flot.bio/episode/otello-stampacchia-omega-funds/Fabrice Chouraqui, Pharming 🇳🇱 | Transgenic Rabbits, Rare Diseases | E43: https://flot.bio/episode/fabrice-chouraqui-pharming-transgenic-rabbit/Laurent Levy, Nanobiotix 🇫🇷 | Nanoparticles, Radiotherapy | E45: https://flot.bio/episode/laurent-levy-nanobiotix-nanoparticles-radiotherapy/Marc de Garidel, Abivax | How to make two Billion-dollar exits (“smoothly”) | E09: https://flot.bio/episode/marc-de-garidel-abivax-exit/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/pascal-touchon-jeito/ 💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:02:40] The rise of Kymriah and Ebvallo[00:05:40] CAR-T: crazy innovations and valuations[00:20:35] Solid tumor challenges[00:23:18] Cell therapy manufacturing and in vivo CAR-T[00:31:38] Catching the innovation wave at Jeito Capital[00:39:29] VC models and European biotech gems[00:52:51] Biotech without borders[01:05:49] France’s rising pharma stars [01:08:30] Quick-fire questions

Pascal Touchon unpacks why the next CAR-T innovations, including allogeneic and in vivo therapies, are going to be so exciting.The cell therapy master outlines his central role in bringing two first‑in‑class cell therapies to patients: Kymriah, the first approved CAR‑T, and Ebvallo, the first approved allogeneic T‑cell therapy. We also explore his new position as an operating partner at Jeito and how we need to work harder to find Europe’s hidden biotech gems.-----------------------------------------------------------------------Get expert legal advisory support for growing your biotech from Osborne Clarke at https://bit.ly/oc-flotbio----------------------------------------------------------------------⭐️ ABOUT THE SPEAKERWith many years of experience in big pharma, Pascal had top-level positions at Novartis Oncology. He later served as CEO, and most recently Chairman, of Atara Biotherapeutics. Alongside his Jeito role, he sits on the boards of companies including Ipsen, Medincell, Catalym, Xylocor and CDR-Life.🔗 LINKS MENTIONEDJeito’s website: https://www.jeito.life/en/home/Stefano Portolano, Azafaros | Rare Diseases, Small Molecules Revival | E40: https://www.youtube.com/watch?v=gdaPW7xg_qkOtello Stampacchia, Omega Funds 🇮🇹 | Competition, Boston & Pasta | E18: https://flot.bio/episode/otello-stampacchia-omega-funds/Fabrice Chouraqui, Pharming 🇳🇱 | Transgenic Rabbits, Rare Diseases | E43: https://flot.bio/episode/fabrice-chouraqui-pharming-transgenic-rabbit/Laurent Levy, Nanobiotix 🇫🇷 | Nanoparticles, Radiotherapy | E45: https://flot.bio/episode/laurent-levy-nanobiotix-nanoparticles-radiotherapy/Marc de Garidel, Abivax | How to make two Billion-dollar exits (“smoothly”) | E09: https://flot.bio/episode/marc-de-garidel-abivax-exit/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/pascal-touchon-jeito/ 💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:02:40] The rise of Kymriah and Ebvallo[00:05:40] CAR-T: crazy innovations and valuations[00:20:35] Solid tumor challenges[00:23:18] Cell therapy manufacturing and in vivo CAR-T[00:31:38] Catching the innovation wave at Jeito Capital[00:39:29] VC models and European biotech gems[00:52:51] Biotech without borders[01:05:49] France’s rising pharma stars [01:08:30] Quick-fire questions

NOW PLAYING

Pascal Touchon 🇫🇷 | Cell Therapy, Jeito, Kymriah | E49

0:00 1:14:33

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Flot.bio x Philip Hemme?

This episode is 1 hour and 14 minutes long.

When was this Flot.bio x Philip Hemme episode published?

This episode was published on January 6, 2026.

What is this episode about?

Pascal Touchon unpacks why the next CAR-T innovations, including allogeneic and in vivo therapies, are going to be so exciting.The cell therapy master outlines his central role in bringing two first‑in‑class cell therapies to patients: Kymriah, the...

Can I download this Flot.bio x Philip Hemme episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!